[
  {
    "ts": null,
    "headline": "Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN)",
    "summary": "Recently, Regeneron Pharmaceuticals saw a wave of analyst upgrades from major banks such as Bank of America Securities and Citi, reflecting increased confidence in the company's outlook ahead of its upcoming fourth-quarter 2025 results announcement on January 30, 2026. An interesting shift alongside these upgrades is the decline in short interest to a level well below peers, suggesting fewer investors are positioning for downside despite ongoing earnings and regulatory uncertainties. With...",
    "url": "https://finnhub.io/api/news?id=3d4bfa598d53f171119068a8f479da06149f6f310900a218ae7c68b1c5ccdb40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767824225,
      "headline": "Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN)",
      "id": 138033529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Recently, Regeneron Pharmaceuticals saw a wave of analyst upgrades from major banks such as Bank of America Securities and Citi, reflecting increased confidence in the company's outlook ahead of its upcoming fourth-quarter 2025 results announcement on January 30, 2026. An interesting shift alongside these upgrades is the decline in short interest to a level well below peers, suggesting fewer investors are positioning for downside despite ongoing earnings and regulatory uncertainties. With...",
      "url": "https://finnhub.io/api/news?id=3d4bfa598d53f171119068a8f479da06149f6f310900a218ae7c68b1c5ccdb40"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines.",
    "summary": "Regeneron Pharmaceuticals  stock has trailed behind the broader market over the past year, but there may be a cure for its malaise.  The drugmaker has posted an 11% gain in a 12-month period.  BofA  Securities has an answer to that.",
    "url": "https://finnhub.io/api/news?id=17a5d0c8741257ba23303cf02f6cab8b3f36cf93c542c50c494f8b23b91b1eec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767819900,
      "headline": "Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines.",
      "id": 138033114,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals  stock has trailed behind the broader market over the past year, but there may be a cure for its malaise.  The drugmaker has posted an 11% gain in a 12-month period.  BofA  Securities has an answer to that.",
      "url": "https://finnhub.io/api/news?id=17a5d0c8741257ba23303cf02f6cab8b3f36cf93c542c50c494f8b23b91b1eec"
    }
  },
  {
    "ts": null,
    "headline": "Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?",
    "summary": "Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=6f4f2ff1d89957777712fed43dc0692b1a760bebff3619ce9c269066185d6a25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767805803,
      "headline": "Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?",
      "id": 138033531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=6f4f2ff1d89957777712fed43dc0692b1a760bebff3619ce9c269066185d6a25"
    }
  },
  {
    "ts": null,
    "headline": "REGN vs. ILMN: Which Stock Is the Better Value Option?",
    "summary": "REGN vs. ILMN: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=a22957e72390cc91f488ffb1557a55af2ecf8182fd8cbcb2a1d5dfd52d2e756d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767804006,
      "headline": "REGN vs. ILMN: Which Stock Is the Better Value Option?",
      "id": 138033532,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN vs. ILMN: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=a22957e72390cc91f488ffb1557a55af2ecf8182fd8cbcb2a1d5dfd52d2e756d"
    }
  },
  {
    "ts": null,
    "headline": "Why Regeneron (REGN) Stock Is Trading Up Today",
    "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the morning session after Bank of America Securities upgraded its rating on the company's stock from 'Underperform' to 'Buy' and significantly raised its price target. The firm's analyst, Tim Anderson, lifted the price target to $860.00 from a previous $627.00. This move signaled growing confidence in Regeneron's market prospects. Adding to the positive sentiment, Citi also raised its price target on the shares to $900 from $700 wh",
    "url": "https://finnhub.io/api/news?id=28565cc0bfd717bf2ae1ab306a222cd237e776c1ac8a032f0422b718a3574e86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767802854,
      "headline": "Why Regeneron (REGN) Stock Is Trading Up Today",
      "id": 138033533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the morning session after Bank of America Securities upgraded its rating on the company's stock from 'Underperform' to 'Buy' and significantly raised its price target. The firm's analyst, Tim Anderson, lifted the price target to $860.00 from a previous $627.00. This move signaled growing confidence in Regeneron's market prospects. Adding to the positive sentiment, Citi also raised its price target on the shares to $900 from $700 wh",
      "url": "https://finnhub.io/api/news?id=28565cc0bfd717bf2ae1ab306a222cd237e776c1ac8a032f0422b718a3574e86"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says",
    "summary": "Regeneron Pharmaceuticals (REGN)'s Eylea HD has had some recent label updates, including an approval",
    "url": "https://finnhub.io/api/news?id=9c52f5b50ae2155a596c15f5f83ad699a1d42e7bad2e93d35217ff7c576187d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767801268,
      "headline": "Regeneron Pharmaceuticals to Have Multiple Pipeline Updates in 2026, BofA Says",
      "id": 138027120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN)'s Eylea HD has had some recent label updates, including an approval",
      "url": "https://finnhub.io/api/news?id=9c52f5b50ae2155a596c15f5f83ad699a1d42e7bad2e93d35217ff7c576187d2"
    }
  },
  {
    "ts": null,
    "headline": "Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls",
    "summary": "Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=f20ffbbfc3ec081a5a29c6fb92dfe098f218cd075292cfab435acb6fdf36ab24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767796867,
      "headline": "Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls",
      "id": 138027184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=f20ffbbfc3ec081a5a29c6fb92dfe098f218cd075292cfab435acb6fdf36ab24"
    }
  },
  {
    "ts": null,
    "headline": "BrightInsight’s Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence",
    "summary": "SAN JOSE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrightInsight, Inc. (“BrightInsight”), a leader in digital health solutions, today shared new data from its collaboration with Sanofi and its partner, Regeneron, highlighting the positive impact of the Patient App on adherence and persistence for one of Sanofi and Regeneron’s key biologic therapies. Adherence remains a major challenge for the pharmaceutical industry—particularly with self-injected therapies administered at home. Despite substan",
    "url": "https://finnhub.io/api/news?id=600316a58aff210dacd4da966508f6a1ab9e4520577c4bf6b58b08107d1a7615",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767792600,
      "headline": "BrightInsight’s Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence",
      "id": 138027310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "SAN JOSE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrightInsight, Inc. (“BrightInsight”), a leader in digital health solutions, today shared new data from its collaboration with Sanofi and its partner, Regeneron, highlighting the positive impact of the Patient App on adherence and persistence for one of Sanofi and Regeneron’s key biologic therapies. Adherence remains a major challenge for the pharmaceutical industry—particularly with self-injected therapies administered at home. Despite substan",
      "url": "https://finnhub.io/api/news?id=600316a58aff210dacd4da966508f6a1ab9e4520577c4bf6b58b08107d1a7615"
    }
  },
  {
    "ts": null,
    "headline": "BofA double-upgrades Regeneron, citing stronger Eylea outlook and 2026 catalysts",
    "summary": "Investing.com -- Bank of America has shifted its stance on Regeneron, raising the stock two notches to Buy from Underperform and lifting its price objective to $860 in a note on Wednesday.",
    "url": "https://finnhub.io/api/news?id=e9a23b8d8ffe1362d8fe58750e351e6aa93c719edf40ee5604ca363f3c31e99e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767789425,
      "headline": "BofA double-upgrades Regeneron, citing stronger Eylea outlook and 2026 catalysts",
      "id": 138027311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investing.com -- Bank of America has shifted its stance on Regeneron, raising the stock two notches to Buy from Underperform and lifting its price objective to $860 in a note on Wednesday.",
      "url": "https://finnhub.io/api/news?id=e9a23b8d8ffe1362d8fe58750e351e6aa93c719edf40ee5604ca363f3c31e99e"
    }
  }
]